Compliance
This section focuses on health care compliance and regulations – both national and state – including the ACA. It includes changes in health care law, regulation, and court decisions and their impact on health insurance professionals, employers, and individuals.
Many insurers have lost money on the Affordable Care Act plans they sell to consumers. A new analysis shows how much those losses deepened in 2015, the second year of the law’s signature exchanges.
This week I answer readers’ questions about buying plans off the insurance marketplaces and more general questions about coverage.
California’s health insurance exchange estimates that its Obamacare premiums may rise 8 percent on average next year, which would end two consecutive years of more modest 4 percent increases.
Federal district Judge Rosemary Collyer, a Republican appointee, ruled that the law does not provide for the funds insurers need to make health insurance policies under the program affordable.
Health insurers and patients could safely save many billions of dollars annually by swapping out a more expensive drug for a less expensive generic in the same class of drugs, according to a study published Monday.
The Department of Health and Human Services (HHS) is tightening the rules for certain SEPs and clarifying that SEPs are only available in six defined and limited types of circumstances. Please read below for details regarding the new rules being implemented.
Nightmare stories of nurses giving potent drugs meant for one patient to another and surgeons removing the wrong body parts have dominated recent headlines about medical care. Lest you assume those cases are the exceptions, a new study by patient-safety researchers provides some context.
Insurers will seek significant premium hikes under President Barack Obama’s health care law this summer — stiff medicine for consumers and voters ahead of the national political conventions.
There are few things as flat out baffling as a medical bill.
Health insurers and patients could safely save many billions of dollars annually by swapping out a more expensive drug for a less expensive generic in the same class of drugs, according to a study published Monday.